Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19

Abstract The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19. Structures of the main protease of SARS-CoV-2 (Mpro), responsible for the replication of the virus, have been solved and quickly made available, thus allowing the design of compounds that could interact with this protease and thus to prevent the progression of the disease by avoiding the viral peptide to be cleaved, so that smaller viral proteins can be released into the host's plasma. These structural data are extremely important for in silico design and development of compounds as well, being possible to quick and effectively identify potential inhibitors addressed to such enzyme's structure. Therefore, in order to identify potential inhibitors for Mpro, we used virtual screening approaches based with the structure of the enzyme and two compounds libraries, targeted to SARS-CoV-2, containing compounds with predicted activity against Mpro. In this way, we selected, through docking studies, the 100 top-ranked compounds, which followed for subsequent studies of pharmacokinetic and toxicity predictions. After all the simulations and predictions here performed, we obtained 10 top-ranked compounds that were again in silico analyzed inside the Mpro catalytic site, together some drugs that are being currently investigated for treatment of COVID-19. After proposing and analyzing the interaction modes of these compounds, we submitted one molecule then selected as template to a 2D similarity study in a database containing drugs approved by FDA and we have found and indicated Apixaban as a potential drug for future treatment of COVID-19.

[1]  R. Tehrani,et al.  Ocular Toxicity of Hydroxychloroquine , 2008, Seminars in ophthalmology.

[2]  Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs , 2020 .

[3]  T. R. Carson,et al.  The effects of continuous exposure of animals to ethanolamine vapor. , 1960, Technical report. CWLR. U.S. Army Chemical Warfare Laboratories.

[4]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[5]  Wolfgang Muster,et al.  Computational toxicology in drug development. , 2008, Drug discovery today.

[6]  J E Ridings,et al.  Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. , 1996, Toxicology.

[7]  Ruiyun Li,et al.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.

[8]  Hualiang Jiang,et al.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease , 2020, Science.

[9]  Jerônimo Lameira,et al.  In silico identification of natural products with anticancer activity using a chemo-structural database of Brazilian biodiversity , 2019, Comput. Biol. Chem..

[10]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[11]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[12]  Jürgen Bajorath,et al.  Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.

[13]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[14]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[15]  V. Hornak,et al.  Targeting structural flexibility in HIV-1 protease inhibitor binding. , 2007, Drug discovery today.

[16]  Sharon Einav,et al.  A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.

[17]  T. Velavan,et al.  The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.

[18]  Z Fazeel.  Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile , 2016 .

[19]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[20]  Markus A. Lill,et al.  Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds , 2020 .

[21]  Gorjan Alagic,et al.  #p , 2019, Quantum information & computation.

[22]  Rolf Hilgenfeld,et al.  Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain , 2002, The EMBO journal.

[23]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[24]  Jürgen Bajorath,et al.  Combinatorial Preferences Affect Molecular Similarity/Diversity Calculations Using Binary Fingerprints and Tanimoto Coefficients , 2000, J. Chem. Inf. Comput. Sci..

[25]  L. Hage-Melim,et al.  Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa , 2017, ChemMedChem.

[26]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[27]  Luis de Sisternes,et al.  Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. , 2015, Investigative ophthalmology & visual science.

[28]  Wenjie Tan,et al.  A distinct name is needed for the new coronavirus , 2020, The Lancet.

[29]  A. Lefor,et al.  Favipiravir: A New Medication for the Ebola Virus Disease Pandemic , 2014, Disaster Medicine and Public Health Preparedness.

[30]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[31]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[32]  Jonathan F. Swanson,et al.  COVID‐19: A review of therapeutics under investigation , 2020, Journal of the American College of Emergency Physicians open.

[33]  G. Whittaker,et al.  Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.

[34]  D. Shin,et al.  Inhibition of SARS-CoV 3CL protease by flavonoids , 2019, Journal of enzyme inhibition and medicinal chemistry.

[35]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[36]  G. Morris,et al.  Molecular docking. , 2008, Methods in molecular biology.

[37]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[38]  Artem Cherkasov,et al.  Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds , 2020, Molecular informatics.

[39]  K. Yuen,et al.  Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases , 2005, PLoS Biology.

[40]  D. Atar,et al.  Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. , 2019, Circulation.

[41]  H. Narita,et al.  In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705 , 2002, Antimicrobial Agents and Chemotherapy.

[42]  Ftlo Bonin-Cecelia,et al.  Phase II: , 2020, The Power of Accountability.

[43]  I. Sola,et al.  Coronavirus reverse genetic systems: Infectious clones and replicons , 2014, Virus Research.

[44]  V. Corman,et al.  Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.

[45]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[46]  Wolfgang Sippl,et al.  Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants , 2016, Drug design, development and therapy.

[47]  Danna Zhou,et al.  d. , 1840, Microbial pathogenesis.

[48]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[49]  M. Gersten,et al.  Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers , 2003, Antimicrobial Agents and Chemotherapy.

[50]  N. Schröder,et al.  Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders , 2011, Psychopharmacology.

[51]  Mubarak A. Alamri,et al.  Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.

[52]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[53]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[54]  P. Sharma,et al.  Dual evaluation of some novel 2-amino-substituted coumarinylthiazoles as anti-inflammatory–antimicrobial agents and their docking studies with COX-1/COX-2 active sites , 2014, Journal of enzyme inhibition and medicinal chemistry.

[55]  P. Andrews,et al.  Virtual screening to identify potent sepiapterin reductase inhibitors. , 2019, Bioorganic & medicinal chemistry letters.

[56]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.